About the Event
In this installment of Psychiatry and Behavioral Sciences Grand Rounds, William H. Reid, M.D., MPH, presents “The Development and Unfortunate Underuse of Clozapine.” Reid is a professor in the Department of Psychiatry and Behavioral Sciences at Dell Medical School.
For more information about the event, email Jennifer Braham.
Upon request, Dell Medical School will provide interpretation services at this event. Please notify Jennifer by Nov. 27, 2024, if interpretation is needed.
Learning Objectives
By the end of this presentation, the audience participant should be able to:
- Understand the clinically-relevant history of clozapine, including development, costs, continuing FDA barriers and psychiatrist misunderstandings.
- Consider clozapine trials for most patients with schizophrenia and similar disorders, not merely “treatment resistant” ones.
- Understand the value of clozapine for decreasing patient mortality and morbidity, increasing patient quality of life and decreasing the overall real, family and social costs of schizophrenia and similar disorders.
Target Audience
- Primary: Psychiatrists, social workers, psychologists, nurses and other mental health professionals
- Secondary: Other health care professionals
Attributes/Competencies
This activity has been designed to promote some of the following desired physician attributes and competencies:
- ACGME: Patient Care; Medical Knowledge; Practice-Based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; Systems-Based Practice
- IOM: Provide Patient-Centered Care; Work in Interdisciplinary Teams; Employ Evidence-Based Practice; Apply Quality Improvement; Utilize Informatics
- IECC: Interprofessional Teamwork and Team-Based Practice; Interprofessional Communication; Values and Ethics for Interprofessional Practice
Speaker Disclosure
William H. Reid, M.D., MPH, speaker for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.
Planner Disclosure
Stephen Sonnenberg, M.D.; Mark H. Townsend, M.D., M.S.; Carol L. Alter, M.D.; Lloyd S. Berg, Ph.D., ABPP; Josh Cisler, Ph.D.; Suzannah Creech, Ph.D.; and Jennifer Braham, M.S., planners for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.
Jeffrey Newport, M.D., M.S., MDiv, planner for this educational activity, received grants/research support from Navitor Pharmaceuticals and Reunion Neurosciences. He serves as a consultant for Sage Therapeutics.
Charles B. Nemeroff, M.D., Ph.D., planner for this educational activity, is a consultant for ANeuroTech (division of Anima BV), Janssen Research & Development LLC, BioXcel Therapeutics, Silo Pharma, Engrail Therapeutics, Clexio Bioscience LTD, EmbarkNeuro (formerly AncoraBio), Galen Mental Health LLC, Goodcap Pharmaceuticals Inc., ITI Inc., Relmada Therapeutics Inc., Sage Therapeutics, Senseye Inc., Abbott Laboratories, Autobahn Therapeutics Inc., EMA Wellness, Guidepoint, and Precisement Health. He is a stock shareholder (directly purchased) of Corcept Therapeutics Pharmaceutical Company, EMA Wellness, Precisement Health, Signant Health, Galen Mental Health, Senseye Inc., and Relmada Therapeutics Inc. Nemeroff is on the scientific advisory boards for ANeuroTech (division of Anima BV), Signant Health, Laureate Institute for Brain Research (LIBR) Inc., LUCY Scientific Discovery, Galen Mental Health LLC, Pasithea Therapeutics Corp, Sage Therapeutics Inc., Skyland Trails, and Senseye Inc. He holds patents for the following: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), Compounds, Compositions, Methods of Synthesis and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2). Nemeroff is the recipient of the following grants: Principal Investigator, National Institute of Alcohol Abuse and Alcoholism/National Institutes of Health Grant 1 R01 AA021090-01A1 Prediction of Alcohol Use Disorder and PTSD after Trauma in Adolescents, 9/1/22-8/31/27; Principal Investigator, Texas Childhood Trauma Research Network, Texas Child Mental Health Consortium SB11, 2019-2021, $2,288,440; 2022-2024; Principal Investigator, National Institute of Mental Health Grant 1 R01MH117292 Understanding PTSD through Postmortem Targeted Brain Multiomics, 12/1/2018-4/30/2023; Co-Principal Investigator, National Institute of Mental Health Grant 1R01MH122387-01A1 Localizing and Modulating Competing Memories of Fear and Safety in the Human Brain, 1/15/2021-12/31/2025; Co-Principal Investigator, National Institute of Mental Health Grant R01MH125886-01 Neurodevelopmental and Clinical Trajectories of Youth at Risk for Bipolar I Disorder, 9/01/2021–8/31/2026.
The CME Advisory Committee, reviewers of this educational activity, do not have relevant financial relationship(s) with ineligible companies to disclose.
All the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas at Austin Dell Medical School designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.